Host cell mTORC1 is required for HCV RNA replication.

Autor:	Stöhr S; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.; German Center for Infection Research (DZIF), Hannover, Germany., Costa R; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany., Sandmann L; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.; German Center for Infection Research (DZIF), Hannover, Germany., Westhaus S; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.; German Center for Infection Research (DZIF), Hannover, Germany.; Institute for Molecular Biology, Medizinische Hochschule Hannover, Hannover, Germany., Pfaender S; Division of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany., Anggakusuma; Division of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany., Dazert E; Cell Growth and Development Biozentrum, Universität Basel, Basel, Switzerland., Meuleman P; Center for Vaccinology, Ghent University, Ghent University Hospital, Ghent, Belgium., Vondran FW; German Center for Infection Research (DZIF), Hannover, Germany.; Department of General, Visceral and Transplantation Surgery, Medizinische Hochschule Hannover, Hannover, Germany., Manns MP; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.; German Center for Infection Research (DZIF), Hannover, Germany., Steinmann E; Division of Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany., von Hahn T; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.; German Center for Infection Research (DZIF), Hannover, Germany.; Institute for Molecular Biology, Medizinische Hochschule Hannover, Hannover, Germany., Ciesek S; Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.; German Center for Infection Research (DZIF), Hannover, Germany.; Integrated Research and Treatment Centre-Transplantation (IFB-Tx), Hannover, Germany.
Jazyk:	angličtina
Zdroj:	Gut [Gut] 2016 Dec; Vol. 65 (12), pp. 2017-2028. Date of Electronic Publication: 2015 Aug 14.
DOI:	10.1136/gutjnl-2014-308971
Abstrakt:	Objective: Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown. Design: We used virological assays to investigate mTOR signalling on the HCV replication cycle. Furthermore, we analysed HCV RNA levels of 42 HCV-positive transplanted patients treated with an mTOR inhibitor as part of their immunosuppressive regimen. Results: The mTOR inhibitor rapamycin was found to be a potent inhibitor for HCV RNA replication in Huh-7.5 cells as well as primary human hepatocytes. Half-maximal inhibition was observed at 0.01 µg/mL, a concentration that is in the range of serum levels seen in transplant recipients and does not affect cell proliferation. Early replication cycle steps such as cell entry and RNA translation were not affected. Knockdown of raptor, an essential component of mTORC1, but not rictor, an essential component of mTORC2, inhibited viral RNA replication. In addition, overexpression of raptor led to higher viral RNA replication, demonstrating that mTORC1, but not mTORC2, is required for HCV RNA replication. In 42 HCV-infected liver-transplanted or kidney-transplanted patients who were switched to an mTOR inhibitor, we could verify that mTOR inhibition decreased HCV RNA levels in vivo. Conclusions: Our data identify mTORC1 as a novel HCV replication factor. These findings suggest an underlying mechanism for the observed benefits of mTOR inhibition in HCV-positive OLT recipients and potentiate further investigation of mTOR-containing regimens in HCV-positive recipients of solid organ transplants. Competing Interests: Conflicts of Interest: None declared. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu